Monthly Archives: March 2014

Human Longevity Inc. (HLI) is a genomics and cell therapy-based diagnostic and therapeutic company. Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the worlds most comprehensive database on human genotypes and phenotypes to tackle the diseases associated with aging-related human biological decline. HLI is also leading the development of cell-based therapeutics to address age-related decline in endogenous stem cell function. HLI is concentrating on cancer, diabetes and obesity, heart and liver diseases, and dementia.

The market for healthy human longevity is enormous. Globally, total healthcare expenses run over $7 trillion, with nearly half of these funds being spent in the senior (65+) years of a persons life to help keep them alive longer. Using the combined power of HLIs core areas of expertise genomics, informatics, and stem cell therapies, HLI is going to change the way medicine is practiced by furthering the shift to a preventive, genomic-based medicine model.

HLI revenue streams will be derived from database licensing to pharmaceutical, biotechnology and academic organizations, sequencing, and development of advanced diagnostics and therapeutics.

HLI has secured $70 million in its initial round of funding. Our investors are a diverse group of individuals and companies who share our common goal and passion of changing healthcare, tackling the diseases of aging, and extending the healthy human lifespan.

The rest is here:
About Human Longevity, Inc.

Human Longevity, Inc. (HLI) is a genomics and cell therapy company focused on extending the healthy, high performance human lifespan. Led by a world-class team of scientific and medical visionaries, HLIs mission is to identify the therapeutically targetable mechanisms responsible for age-related human biological decline and to apply this intelligence to develop innovative solutions to interrupt or block those processes, meaningfully extending the human lifespan.

We are building a database of genotype and phenotype information together with data mining infrastructure, on a scale that has not ever been done before. We are trying to tackle some of the most vexing diseases like cancer, heart disease and diabetes. We are blazing a new trail in science, medicine and research and we need people who, like us, want to change the world. Our founders, along with our scientific and medical teams are impatient for the healthcare of the future. That is why we are working to change the way medicine is practiced through our genomic-focused, preventive model.

We are seeking world-class people who share our passion and want to play an integral role in executing the companys vision. If you are dynamic, innovative, creative, intelligent, and resourceful, consider joining our quest to improve the state of healthcare in the world today.

Continued here:
Careers Human Longevity, Inc.

Co-founders of San Diego based Human Longevity Inc., Peter Diamandis, left, J. Craig Venter, center, and Robert Hariri, right.

It was a bold prediction, even at a time when technology evolves with blinding speed:

Getting your genome sequenced will soon become as common as dropping by a doctors office for a blood test.

The forecast was made Tuesday by three men who have money riding on the outcome: La Jolla geneticist J. Craig Venter, New Jersey stem cell pioneer Dr. Robert Hariri and Peter Diamandis of Los Angeles, founder of the X-Prize Foundation.

They gathered in Venters seaside office to announce that they had founded Human Longevity, Inc. (HLI), which they say will quickly become the largest genome sequencing company in the world, surpassing even Chinas well-known Beijing Genomics Institute.

Venter said that HLI will begin by sequencing 40,000 genomes a year, then push production to 100,000. The work will be done with cutting edge technology from San Diegos Illumina, which has helped to slash the time and cost of sequencing peoples genomes.

Venter and other scientists believe that sequencing the genomes of hundreds of thousands of people will clearly reveal which genes cause disease and illness, leading to better diagnostics and treatment. HLI also will analyze a persons microbes and metabolites, providing doctors with a more comprehensive picture of the patients they treat.

The goal: Enable people to live longer, healthier lives.

100 will become the new 60, Diamandis said in a moment of exuberance.

The remark came as all three men paused to discussion the future of genomic medicine with U-T San Diego.

See the original post:
Will 100 become the new 60?